ANP 650 Advanced Nurse Practitioner Clinical Management
Study Guide, Comprehensive Exam Prep Notes, Case Study
Analysis, and Evidence-Based Practice Review for Graduate
Nursing and Nurse Practitioner Students
Question 1: A 68-year-old male with hypertension, type 2 diabetes, and chronic kidney
disease stage 3 presents with a 2-week history of progressive dyspnea on exertion and
bilateral lower extremity edema. His current medications include lisinopril 20 mg daily,
metformin 1000 mg BID, and atorvastatin 40 mg nightly. Physical exam reveals jugular
venous distension at 10 cm H2O, bibasilar crackles, and 2+ pitting edema to the mid-calf.
Which medication adjustment is most appropriate as initial management for this patient's
acute decompensation?
A. Increase lisinopril to 40 mg daily
B. Add furosemide 40 mg daily
C. Discontinue metformin and start insulin glargine
D. Add spironolactone 25 mg daily
CORRECT ANSWER: B. Add furosemide 40 mg daily
Rationale: This patient presents with signs and symptoms consistent with acute heart failure
exacerbation (elevated JVD, crackles, edema) in the setting of multiple cardiovascular risk
factors. Loop diuretics like furosemide are first-line therapy for volume overload in acute
decompensated heart failure to rapidly reduce preload and relieve symptoms. Increasing
lisinopril could worsen renal function in the setting of acute decompensation and CKD.
Discontinuing metformin may be considered if renal function deteriorates further, but it does
not address the acute volume overload. Spironolactone is beneficial in chronic heart failure
with reduced ejection fraction but is not first-line for acute symptom relief.
Question 2: Which of the following findings is most specific for distinguishing bacterial
pneumonia from viral pneumonia in an adult patient presenting with cough, fever, and
infiltrate on chest X-ray?
A. Presence of pleuritic chest pain
B. Elevated procalcitonin level >0.5 ng/mL
C. White blood cell count of 14,000/mm³
D. Productive cough with yellow sputum
CORRECT ANSWER: B. Elevated procalcitonin level >0.5 ng/mL
Rationale: Procalcitonin is a biomarker that rises more significantly in bacterial infections
compared to viral infections. A level >0.5 ng/mL has good specificity for bacterial pneumonia
and can help guide antibiotic stewardship decisions. Pleuritic chest pain, leukocytosis, and
purulent sputum can occur in both bacterial and viral pneumonias and lack sufficient specificity
for reliable differentiation. Clinical prediction rules incorporating procalcitonin have been
validated to reduce unnecessary antibiotic use in respiratory infections.
Question 3: A 45-year-old female with no significant past medical history presents with a 3-
day history of severe vertigo, nausea, and horizontal nystagmus that worsens with head
movement. She denies hearing loss, tinnitus, or focal neurological deficits. Which diagnosis is
most consistent with this presentation?
,A. Meniere's disease
B. Vestibular neuritis
C. Benign paroxysmal positional vertigo (BPPV)
D. Acoustic neuroma
CORRECT ANSWER: B. Vestibular neuritis
Rationale: Vestibular neuritis typically presents with acute, persistent vertigo lasting days to
weeks, associated with nausea/vomiting, horizontal-torsional nystagmus, and worsening with
head movement, without auditory symptoms. BPPV causes brief episodes of vertigo (<1
minute) triggered by specific head positions, not persistent symptoms. Meniere's disease
includes episodic vertigo with fluctuating hearing loss, tinnitus, and aural fullness. Acoustic
neuroma typically presents with progressive unilateral hearing loss and tinnitus, with vertigo
being less prominent.
Question 4: According to the 2023 ACC/AHA guidelines, which of the following is the
recommended first-line pharmacologic therapy for a patient with newly diagnosed heart
failure with reduced ejection fraction (HFrEF) and no contraindications?
A. Beta-blocker alone
B. ACE inhibitor or ARB alone
C. Quadruple therapy: ACEi/ARB/ARNI, beta-blocker, MRA, and SGLT2 inhibitor
D. Diuretic therapy followed by ACE inhibitor
CORRECT ANSWER: C. Quadruple therapy: ACEi/ARB/ARNI, beta-blocker, MRA, and SGLT2
inhibitor
Rationale: Current ACC/AHA guidelines recommend initiating four foundational medication
classes simultaneously (or in rapid sequence) for HFrEF: renin-angiotensin system inhibition
(ACEi/ARB/ARNI), evidence-based beta-blocker, mineralocorticoid receptor antagonist, and
SGLT2 inhibitor. This "quadruple therapy" approach has been shown to significantly reduce
mortality and hospitalizations compared to sequential initiation. Diuretics are used for
symptom management of volume overload but do not modify disease progression.
Question 5: A 72-year-old male with atrial fibrillation is being evaluated for anticoagulation.
His CHA₂DS₂-VASc score is 4. He has a history of peptic ulcer disease but no active bleeding.
Which anticoagulant is most appropriate for stroke prevention in this patient?
A. Warfarin with target INR 2.0-3.0
B. Apixaban 5 mg BID
C. Aspirin 325 mg daily
D. Clopidogrel 75 mg daily
CORRECT ANSWER: B. Apixaban 5 mg BID
Rationale: For non-valvular atrial fibrillation with CHA₂DS₂-VASc ≥2 in males, direct oral
anticoagulants (DOACs) like apixaban are preferred over warfarin due to superior safety
profiles, particularly lower intracranial hemorrhage risk. Apixaban has demonstrated lower
gastrointestinal bleeding risk compared to other DOACs and warfarin, making it favorable in
patients with prior PUD. Aspirin and clopidogrel are inferior to anticoagulation for stroke
prevention in AF and are not recommended as monotherapy for this indication.
,Question 6: Which of the following laboratory findings is most consistent with primary
adrenal insufficiency (Addison's disease)?
A. Hypernatremia, hypokalemia, elevated morning cortisol
B. Hyponatremia, hyperkalemia, elevated ACTH, low morning cortisol
C. Hyponatremia, hypokalemia, low ACTH, low morning cortisol
D. Normal sodium/potassium, low ACTH, low morning cortisol
CORRECT ANSWER: B. Hyponatremia, hyperkalemia, elevated ACTH, low morning cortisol
Rationale: Primary adrenal insufficiency involves adrenal gland destruction, leading to deficient
cortisol and aldosterone production. This causes hyponatremia (from cortisol deficiency
impairing free water clearance and aldosterone deficiency), hyperkalemia (aldosterone
deficiency), elevated ACTH (loss of negative feedback), and low morning cortisol. Secondary
adrenal insufficiency (pituitary origin) shows low ACTH with low cortisol but typically normal
electrolytes since aldosterone is primarily regulated by RAAS, not ACTH.
Question 7: A 34-year-old female presents with fatigue, weight gain, cold intolerance, and
constipation. Physical exam reveals dry skin, delayed deep tendon reflexes, and a diffusely
enlarged, non-tender thyroid. TSH is 18.5 mIU/L (elevated) and free T4 is low. Which of the
following is the most appropriate initial treatment?
A. Levothyroxine 25 mcg daily, titrate based on TSH
B. Levothyroxine 150 mcg daily immediately
C. Liothyronine (T3) therapy
D. Thyroid ultrasound before initiating treatment
CORRECT ANSWER: A. Levothyroxine 25 mcg daily, titrate based on TSH
Rationale: This patient has clinical and laboratory findings consistent with primary
hypothyroidism, likely Hashimoto's thyroiditis. Levothyroxine (T4) is the standard treatment.
Starting with a low dose (25-50 mcg) is recommended, especially in younger patients without
cardiac disease, with titration every 6-8 weeks based on TSH until target range is achieved.
Starting with a full replacement dose risks overtreatment and cardiac complications. T3 therapy
is not first-line. Ultrasound is not required for diagnosis when clinical and biochemical findings
are classic.
Question 8: Which of the following is the most appropriate screening recommendation for
colorectal cancer in an average-risk 46-year-old patient with no family history?
A. Colonoscopy every 10 years starting at age 45
B. Annual fecal immunochemical test (FIT) starting at age 45
C. CT colonography every 5 years starting at age 50
D. Flexible sigmoidoscopy every 10 years starting at age 50
CORRECT ANSWER: A. Colonoscopy every 10 years starting at age 45
Rationale: Current USPSTF and ACS guidelines recommend initiating colorectal cancer screening
at age 45 for average-risk individuals. Colonoscopy every 10 years is a preferred option with the
advantage of both screening and therapeutic capability. FIT annually is also acceptable but
requires strict adherence. CT colonography and flexible sigmoidoscopy are alternative options
but less commonly first-line. Starting at age 50 is outdated per current guidelines.
, Question 9: A patient with type 2 diabetes and established atherosclerotic cardiovascular
disease is being optimized for glycemic control. Which medication class has demonstrated
cardiovascular outcome benefits independent of glycemic effects?
A. Sulfonylureas
B. DPP-4 inhibitors
C. SGLT2 inhibitors
D. Meglitinides
CORRECT ANSWER: C. SGLT2 inhibitors
Rationale: SGLT2 inhibitors (e.g., empagliflozin, canagliflozin) and GLP-1 receptor agonists have
robust cardiovascular outcome trial data showing reduction in major adverse cardiovascular
events, heart failure hospitalization, and/or cardiovascular mortality in patients with type 2
diabetes and ASCVD. These benefits appear partially independent of glucose lowering.
Sulfonylureas, DPP-4 inhibitors, and meglitinides have not demonstrated consistent
cardiovascular benefits and may have neutral or potentially adverse effects in some
populations.
Question 10: Which of the following is a contraindication to the use of metformin in a patient
with type 2 diabetes?
A. eGFR of 45 mL/min/1.73m²
B. History of mild, stable heart failure
C. Acute decompensated heart failure requiring hospitalization
D. Age over 75 years
CORRECT ANSWER: C. Acute decompensated heart failure requiring hospitalization
Rationale: Metformin is contraindicated in conditions that increase the risk of lactic acidosis,
including acute decompensated heart failure, severe renal impairment (eGFR <30), acute liver
failure, and conditions causing tissue hypoxia. Current guidelines allow metformin use in stable
heart failure and in patients with eGFR 30-45 with dose adjustment and monitoring. Age alone
is not a contraindication; renal function and clinical stability are the determining factors.
Question 11: A 58-year-old male presents with substernal chest pressure radiating to the left
arm, diaphoresis, and nausea for 45 minutes. ECG shows ST-segment elevation in leads II, III,
and aVF. Which of the following is the most time-sensitive intervention?
A. Administer sublingual nitroglycerin
B. Obtain serial cardiac biomarkers
C. Activate the cardiac catheterization lab for primary PCI
D. Start intravenous beta-blocker therapy
CORRECT ANSWER: C. Activate the cardiac catheterization lab for primary PCI
Rationale: This patient has an acute inferior ST-elevation myocardial infarction (STEMI). Primary
percutaneous coronary intervention (PCI) is the preferred reperfusion strategy when available
within guideline-recommended timeframes (door-to-balloon time <90 minutes). Time to
reperfusion is the strongest modifiable predictor of mortality in STEMI. Nitroglycerin and beta-
blockers may be used adjunctively but do not replace reperfusion. Cardiac biomarkers confirm
diagnosis but should not delay reperfusion therapy.
Study Guide, Comprehensive Exam Prep Notes, Case Study
Analysis, and Evidence-Based Practice Review for Graduate
Nursing and Nurse Practitioner Students
Question 1: A 68-year-old male with hypertension, type 2 diabetes, and chronic kidney
disease stage 3 presents with a 2-week history of progressive dyspnea on exertion and
bilateral lower extremity edema. His current medications include lisinopril 20 mg daily,
metformin 1000 mg BID, and atorvastatin 40 mg nightly. Physical exam reveals jugular
venous distension at 10 cm H2O, bibasilar crackles, and 2+ pitting edema to the mid-calf.
Which medication adjustment is most appropriate as initial management for this patient's
acute decompensation?
A. Increase lisinopril to 40 mg daily
B. Add furosemide 40 mg daily
C. Discontinue metformin and start insulin glargine
D. Add spironolactone 25 mg daily
CORRECT ANSWER: B. Add furosemide 40 mg daily
Rationale: This patient presents with signs and symptoms consistent with acute heart failure
exacerbation (elevated JVD, crackles, edema) in the setting of multiple cardiovascular risk
factors. Loop diuretics like furosemide are first-line therapy for volume overload in acute
decompensated heart failure to rapidly reduce preload and relieve symptoms. Increasing
lisinopril could worsen renal function in the setting of acute decompensation and CKD.
Discontinuing metformin may be considered if renal function deteriorates further, but it does
not address the acute volume overload. Spironolactone is beneficial in chronic heart failure
with reduced ejection fraction but is not first-line for acute symptom relief.
Question 2: Which of the following findings is most specific for distinguishing bacterial
pneumonia from viral pneumonia in an adult patient presenting with cough, fever, and
infiltrate on chest X-ray?
A. Presence of pleuritic chest pain
B. Elevated procalcitonin level >0.5 ng/mL
C. White blood cell count of 14,000/mm³
D. Productive cough with yellow sputum
CORRECT ANSWER: B. Elevated procalcitonin level >0.5 ng/mL
Rationale: Procalcitonin is a biomarker that rises more significantly in bacterial infections
compared to viral infections. A level >0.5 ng/mL has good specificity for bacterial pneumonia
and can help guide antibiotic stewardship decisions. Pleuritic chest pain, leukocytosis, and
purulent sputum can occur in both bacterial and viral pneumonias and lack sufficient specificity
for reliable differentiation. Clinical prediction rules incorporating procalcitonin have been
validated to reduce unnecessary antibiotic use in respiratory infections.
Question 3: A 45-year-old female with no significant past medical history presents with a 3-
day history of severe vertigo, nausea, and horizontal nystagmus that worsens with head
movement. She denies hearing loss, tinnitus, or focal neurological deficits. Which diagnosis is
most consistent with this presentation?
,A. Meniere's disease
B. Vestibular neuritis
C. Benign paroxysmal positional vertigo (BPPV)
D. Acoustic neuroma
CORRECT ANSWER: B. Vestibular neuritis
Rationale: Vestibular neuritis typically presents with acute, persistent vertigo lasting days to
weeks, associated with nausea/vomiting, horizontal-torsional nystagmus, and worsening with
head movement, without auditory symptoms. BPPV causes brief episodes of vertigo (<1
minute) triggered by specific head positions, not persistent symptoms. Meniere's disease
includes episodic vertigo with fluctuating hearing loss, tinnitus, and aural fullness. Acoustic
neuroma typically presents with progressive unilateral hearing loss and tinnitus, with vertigo
being less prominent.
Question 4: According to the 2023 ACC/AHA guidelines, which of the following is the
recommended first-line pharmacologic therapy for a patient with newly diagnosed heart
failure with reduced ejection fraction (HFrEF) and no contraindications?
A. Beta-blocker alone
B. ACE inhibitor or ARB alone
C. Quadruple therapy: ACEi/ARB/ARNI, beta-blocker, MRA, and SGLT2 inhibitor
D. Diuretic therapy followed by ACE inhibitor
CORRECT ANSWER: C. Quadruple therapy: ACEi/ARB/ARNI, beta-blocker, MRA, and SGLT2
inhibitor
Rationale: Current ACC/AHA guidelines recommend initiating four foundational medication
classes simultaneously (or in rapid sequence) for HFrEF: renin-angiotensin system inhibition
(ACEi/ARB/ARNI), evidence-based beta-blocker, mineralocorticoid receptor antagonist, and
SGLT2 inhibitor. This "quadruple therapy" approach has been shown to significantly reduce
mortality and hospitalizations compared to sequential initiation. Diuretics are used for
symptom management of volume overload but do not modify disease progression.
Question 5: A 72-year-old male with atrial fibrillation is being evaluated for anticoagulation.
His CHA₂DS₂-VASc score is 4. He has a history of peptic ulcer disease but no active bleeding.
Which anticoagulant is most appropriate for stroke prevention in this patient?
A. Warfarin with target INR 2.0-3.0
B. Apixaban 5 mg BID
C. Aspirin 325 mg daily
D. Clopidogrel 75 mg daily
CORRECT ANSWER: B. Apixaban 5 mg BID
Rationale: For non-valvular atrial fibrillation with CHA₂DS₂-VASc ≥2 in males, direct oral
anticoagulants (DOACs) like apixaban are preferred over warfarin due to superior safety
profiles, particularly lower intracranial hemorrhage risk. Apixaban has demonstrated lower
gastrointestinal bleeding risk compared to other DOACs and warfarin, making it favorable in
patients with prior PUD. Aspirin and clopidogrel are inferior to anticoagulation for stroke
prevention in AF and are not recommended as monotherapy for this indication.
,Question 6: Which of the following laboratory findings is most consistent with primary
adrenal insufficiency (Addison's disease)?
A. Hypernatremia, hypokalemia, elevated morning cortisol
B. Hyponatremia, hyperkalemia, elevated ACTH, low morning cortisol
C. Hyponatremia, hypokalemia, low ACTH, low morning cortisol
D. Normal sodium/potassium, low ACTH, low morning cortisol
CORRECT ANSWER: B. Hyponatremia, hyperkalemia, elevated ACTH, low morning cortisol
Rationale: Primary adrenal insufficiency involves adrenal gland destruction, leading to deficient
cortisol and aldosterone production. This causes hyponatremia (from cortisol deficiency
impairing free water clearance and aldosterone deficiency), hyperkalemia (aldosterone
deficiency), elevated ACTH (loss of negative feedback), and low morning cortisol. Secondary
adrenal insufficiency (pituitary origin) shows low ACTH with low cortisol but typically normal
electrolytes since aldosterone is primarily regulated by RAAS, not ACTH.
Question 7: A 34-year-old female presents with fatigue, weight gain, cold intolerance, and
constipation. Physical exam reveals dry skin, delayed deep tendon reflexes, and a diffusely
enlarged, non-tender thyroid. TSH is 18.5 mIU/L (elevated) and free T4 is low. Which of the
following is the most appropriate initial treatment?
A. Levothyroxine 25 mcg daily, titrate based on TSH
B. Levothyroxine 150 mcg daily immediately
C. Liothyronine (T3) therapy
D. Thyroid ultrasound before initiating treatment
CORRECT ANSWER: A. Levothyroxine 25 mcg daily, titrate based on TSH
Rationale: This patient has clinical and laboratory findings consistent with primary
hypothyroidism, likely Hashimoto's thyroiditis. Levothyroxine (T4) is the standard treatment.
Starting with a low dose (25-50 mcg) is recommended, especially in younger patients without
cardiac disease, with titration every 6-8 weeks based on TSH until target range is achieved.
Starting with a full replacement dose risks overtreatment and cardiac complications. T3 therapy
is not first-line. Ultrasound is not required for diagnosis when clinical and biochemical findings
are classic.
Question 8: Which of the following is the most appropriate screening recommendation for
colorectal cancer in an average-risk 46-year-old patient with no family history?
A. Colonoscopy every 10 years starting at age 45
B. Annual fecal immunochemical test (FIT) starting at age 45
C. CT colonography every 5 years starting at age 50
D. Flexible sigmoidoscopy every 10 years starting at age 50
CORRECT ANSWER: A. Colonoscopy every 10 years starting at age 45
Rationale: Current USPSTF and ACS guidelines recommend initiating colorectal cancer screening
at age 45 for average-risk individuals. Colonoscopy every 10 years is a preferred option with the
advantage of both screening and therapeutic capability. FIT annually is also acceptable but
requires strict adherence. CT colonography and flexible sigmoidoscopy are alternative options
but less commonly first-line. Starting at age 50 is outdated per current guidelines.
, Question 9: A patient with type 2 diabetes and established atherosclerotic cardiovascular
disease is being optimized for glycemic control. Which medication class has demonstrated
cardiovascular outcome benefits independent of glycemic effects?
A. Sulfonylureas
B. DPP-4 inhibitors
C. SGLT2 inhibitors
D. Meglitinides
CORRECT ANSWER: C. SGLT2 inhibitors
Rationale: SGLT2 inhibitors (e.g., empagliflozin, canagliflozin) and GLP-1 receptor agonists have
robust cardiovascular outcome trial data showing reduction in major adverse cardiovascular
events, heart failure hospitalization, and/or cardiovascular mortality in patients with type 2
diabetes and ASCVD. These benefits appear partially independent of glucose lowering.
Sulfonylureas, DPP-4 inhibitors, and meglitinides have not demonstrated consistent
cardiovascular benefits and may have neutral or potentially adverse effects in some
populations.
Question 10: Which of the following is a contraindication to the use of metformin in a patient
with type 2 diabetes?
A. eGFR of 45 mL/min/1.73m²
B. History of mild, stable heart failure
C. Acute decompensated heart failure requiring hospitalization
D. Age over 75 years
CORRECT ANSWER: C. Acute decompensated heart failure requiring hospitalization
Rationale: Metformin is contraindicated in conditions that increase the risk of lactic acidosis,
including acute decompensated heart failure, severe renal impairment (eGFR <30), acute liver
failure, and conditions causing tissue hypoxia. Current guidelines allow metformin use in stable
heart failure and in patients with eGFR 30-45 with dose adjustment and monitoring. Age alone
is not a contraindication; renal function and clinical stability are the determining factors.
Question 11: A 58-year-old male presents with substernal chest pressure radiating to the left
arm, diaphoresis, and nausea for 45 minutes. ECG shows ST-segment elevation in leads II, III,
and aVF. Which of the following is the most time-sensitive intervention?
A. Administer sublingual nitroglycerin
B. Obtain serial cardiac biomarkers
C. Activate the cardiac catheterization lab for primary PCI
D. Start intravenous beta-blocker therapy
CORRECT ANSWER: C. Activate the cardiac catheterization lab for primary PCI
Rationale: This patient has an acute inferior ST-elevation myocardial infarction (STEMI). Primary
percutaneous coronary intervention (PCI) is the preferred reperfusion strategy when available
within guideline-recommended timeframes (door-to-balloon time <90 minutes). Time to
reperfusion is the strongest modifiable predictor of mortality in STEMI. Nitroglycerin and beta-
blockers may be used adjunctively but do not replace reperfusion. Cardiac biomarkers confirm
diagnosis but should not delay reperfusion therapy.
